University of Illinois Urbana-Champaign

Exon skipping therapy for Duchenne Muscular Dystrophy with CRISPR base editors

Gapinske, Michael Paul

Content Files
GAPINSKE-DISSERTATION-2022.pdf

Permalink

https://hdl.handle.net/2142/115531

Description

Title
Exon skipping therapy for Duchenne Muscular Dystrophy with CRISPR base editors
Author(s)
Gapinske, Michael Paul
Issue Date
2022-04-13
Director of Research (if dissertation) or Advisor (if thesis)
Perez-Pinera, Pablo
Doctoral Committee Chair(s)
Perez-Pinera, Pablo
Committee Member(s)
  • Gaj, Thomas
  • Smith, Andrew M
  • Song, Jun S
Department of Study
Bioengineering
Discipline
Bioengineering
Degree Granting Institution
University of Illinois at Urbana-Champaign
Degree Name
Ph.D.
Degree Level
Dissertation
Keyword(s)
  • CRISPR
  • adenine base editors
  • cytidine base editors
  • exon skipping
  • Duchenne Muscular Dystrophy
  • ALS
  • SOD1
  • DMD
Abstract
Duchenne muscular dystrophy is an X-linked monogenic disease caused by mutations in the dystrophin gene (DMD) and characterized by progressive muscle weakness leading to cardiomyopathy and respiratory failure, significantly decreasing life expectancy. Since the current standard of care for Duchenne muscular dystrophy focuses solely on the symptoms of the disease, there is a dire need for novel treatment modalities that can correct the underlying genetic mutations. One such technology is gene therapy, which has been utilized for treating Duchenne muscular dystrophy by delivering heterologous genes, altering mRNA splicing or directly modifying the genome with CRISPR-Cas gene editing systems. Gene editing represents a particularly promising approach that can permanently restore native expression of corrected dystrophin following a single administration of the therapeutic transgenes. Since CRISPR-Cas editing systems that rely on double-strand DNA breaks have been shown to create potentially deleterious chromosomal aberrations, CRISPR base editing technologies are emerging as safer and more precise alternatives. CRISPR base editors have enormous potential for directly correcting point mutations, the most common type of disease-causing genetic variant, as well as for gene knockout. However, this technology has not previously been applied to the most common form of mutation causing Duchenne muscular dystrophy: deletions that shift the reading frame and introduce premature stop codons to the genetic sequence. Additionally, the large size of the genes encoding base editors has previously prevented their delivery via AdenoAssociated Virus (AAV), the most promising gene delivery vector to date. This dissertation first covers the development of CRISPR-SKIP, our strategy using CRISPR base editors to correct frameshift deletions of exons through the skipping of neighboring exons. We next adapt a method of protein trans-splicing to base editing technology, to enable the expression of a single large base editor protein from two genes small enough to deliver by AAV. This technology has great potential to move base editing technology towards the clinic, as we demonstrate with the in vivo knock out of the human SOD1 gene, mutations in which cause Amyotrophic Lateral Sclerosis. Finally, we apply CRISPR-SKIP to correct a frameshift deletion responsible for Duchenne muscular dystrophy and achieve in vivo editing of the same disease-correcting genomic site in mice.
Graduation Semester
2022-05
Type of Resource
Thesis
Handle URL
https://hdl.handle.net/2142/115531
Copyright and License Information
Copyright 2022 Michael Gapinske

Owning Collections

Graduate Dissertations and Theses at Illinois PRIMARY
Graduate Theses and Dissertations at Illinois